Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

05:27 EDT 18 Jun 2019 | Pharmafile

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumours in both adult and paediatric patients, it has emerged.

As well as representing Rozlytrek’s first approval worldwide, the decision also marks the first authorisation of a tumour-agnostic medicine in Japan that targets NTRK gene fusions, which have implications in the treatment of a range of solid tumour types including pancreatic, breast, lung, c

Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumours in both adult and paediatric patients, it has emerged.

More From BioPortfolio on "Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours"